Physician profile

Tarak J Patel

Pediatric Pulmonology · San Antonio, TX

NPI 1013954221

$11,016.36

in general payments reported to CMS, 2019-2025

43 companies · $2,466 in 2025

The $2,466 reported for 2025 was more than what 93% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,268.29
Education$417.26

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Genzyme Corporation $1,885.83 2021-2025
Harmony Biosciences LLC $1,346.25 2020-2025 Wakix
Regeneron Healthcare Solutions, INC. $1,161.80 2019-2025 Dupixent
Glaxosmithkline, LLC. $917.44 2019-2025 Nucala
Astrazeneca Pharmaceuticals Lp $915.31 2019-2025 Fasenra, Tezspire
Jazz Pharmaceuticals INC. $609.21 2019-2025
Baxter Healthcare $577.55 2022-2025 Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System, Hillrom - Volara System
Electromed, INC. $423.47 2019-2025 Smartvest
Amgen INC. $314.14 2021-2025 Tezspire
Pharming Healthcare, INC. $272.70 2023-2025 Ruconest
Avadel Cns Pharmaceuticals, LLC $269.53 2024-2025 Lumryz
Philips North America LLC $266.37 2019-2025 (Ak6) Vest Therapy, Vest Therapy Und
Biogen, INC. $255.71 2019-2025 Spinraza, Spinraza
Advanced Respiratory, INC $185.04 2020-2021
Sobi, INC $146.73 2019-2023
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Alexion Pharmaceuticals, INC. $116.85 2019
Genentech USA, INC. $115.35 2019-2023 Xolair
Abbvie INC. $105.30 2019-2022
Fisher & Paykel Healthcare INC $103.77 2025 Fisher & Paykel Healthcare
Itf Therapeutics LLC $86.67 2024-2025
Blueprint Medicines Corporation $86.53 2025
Novartis Pharmaceuticals Corporation $86.49 2019-2025
Pfizer INC. $80.32 2019
Covis Pharma Gmbh $77.11 2020-2021
Tactile Systems Technology INC $76.51 2022-2024 Flexitouch Plus, Entre Plus
Takeda Pharmaceuticals U.S.A., INC. $67.86 2023-2024 Elaprase, Cuvitru
Insmed, INC. $64.13 2023-2025 Arikayce
Alk-Abello, INC $47.95 2024 Grastek, Ragwitek, Odactra
Sanofi Pasteur INC. $46.00 2024
Phadia US INC. $45.78 2024 Immunocap
Kaleo, INC. $38.62 2020-2023 Auvi-Q
Resmed Corp $33.13 2019
Teva Pharmaceuticals USA, INC. $31.01 2019
3b Medical, INC. $28.01 2025 Luna
Ars Pharmaceuticals Operations, INC. $26.30 2025 Neffy
Photocure INC $23.88 2019
Azurity Pharmaceuticals, INC. $17.86 2025 Alvesco
Karl Storz Endoscopy-America $17.28 2019
Lucid Diagnostics INC. $15.82 2022
Itamar Medical INC $15.59 2022
Boehringer Ingelheim Pharmaceuticals, INC. $15.16 2022

2 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Tarak J Patel

$11,016.36

in general payments reported 2019-2025

Years
2019-2025
Top company
Genzyme Corporation
Context
The $2,466 reported for 2025 was more than what 93% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).

https://glasscript.com/doctor/1188/tarak-j-patel

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.